Time Trends and Excess Mortality Compared to Population Controls after a First-Time Pulmonary Embolism or Deep Vein Thrombosis
Katarina Glise Sandblad,Carl Johan Svensson,Kristina Svennerholm,Jacob Philipson,Aldina Pivodic,Sam Schulman,Mazdak Tavoly
DOI: https://doi.org/10.1055/a-2402-6192
2024-09-14
Thrombosis and Haemostasis
Abstract:Background Recent data on temporal trends in excess mortality for patients with pulmonary embolism (PE) and deep vein thrombosis (DVT) compared with the general population are scarce. Methods A nationwide Swedish register study conducted from 2006 to 2018 including 68,960 PE and 70,949 DVT cases matched with population controls. Poisson regression determined relative risk (RR) for 30-day and 1-year mortality trends while Cox regression determined adjusted hazard ratios (aHRs). A significance level of 0.001 was applied. Results In PE cases, both 30-day mortality (12.5% in 2006 to 7.8% in 2018, RR: 0.95 [95% CI: 0.95–0.96], p < 0.0001) and 1-year mortality (26.5 to 22.1%, RR: 0.98 [0.97–0.98], p < 0.0001) decreased during the study period. Compared with controls, no significant change was seen in 30-day (aHR: 33.08 [95% CI: 25.12–43.55] to 24.64 [95% CI: 18.81–32.27], p = 0.0015 for interaction with calendar year) or 1-year (aHR: 5.85 [95% CI: 5.31–6.45] to 7.07 [95% CI: 6.43–7.78], p = 0.038) excess mortality. The 30-day excess mortality decreased significantly (aHR: 39.93 [95% CI: 28.47–56.00) to 24.63 [95% CI: 17.94–33.83], p = 0.0009) in patients with PE without known cancer before baseline, while the excess 1-year mortality increased (aHR: 3.55 [95% CI: 3.16–3.99] to 5.38 [95% CI: 4.85–5.98], p < 0.0001) in PE cases surviving to fill a prescription of anticoagulation. In DVT cases, 30-day and 1-year mortality declined, while excess mortality compared with controls remained stable. Conclusion In general, the improved mortality following PE and DVT paralleled population trends. However, PE cases without cancer had decreasing excess 30-day mortality, whereas those surviving to fill a prescription for anticoagulant medication showed increasing excess 1-year mortality. The data that support the findings of this study are available from The National Board of Health and Welfare and Statistics, Sweden, but restrictions apply to the availability of these data, so they are not publicly available. K.G.S. planned the study. All authors, particularly M.T. and K.G.S., made important contributions to the design of this study. A.P. preformed statistical analyses. All authors were involved in interpreting the data. K.G.S. wrote the first draft of the manuscript. K.G.S., M.T., J.P., S.S., K.S., and C.J.S. provided clinical input at all stages of the project. All authors, particularly M.T. and K.G.S., reviewed and edited the manuscript. All authors approved the final draft. Received: 20 June 2024 Accepted: 20 August 2024 Accepted Manuscript online: 23 August 2024 Article published online: 12 September 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Stuttgart · New York
peripheral vascular disease,hematology